Here are the DEF 14A proxy statements from Insight Molecular Diagnostics Inc. (IMDX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow IMDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMDX filings page.
Insight Molecular Diagnostics Inc. (iMDx) is asking shareholders to approve four items at its 2026 virtual annual meeting, including re-electing four directors, ratifying CBIZ CPAs as auditor, a non-binding say-on-pay vote, and a 1,750,000-share increase to its 2018 Equity Incentive Plan for a new total of 5,550,000 shares.
The proxy highlights iMDx’s strategy to decentralize transplant organ health monitoring through its dd-cfDNA assay platform. The company has submitted its GraftAssureDx test kit to the FDA for in vitro diagnostic marketing authorization and is running a 5,000-patient registry across 50 hospitals, supported by a partnership with Bio-Rad Laboratories, which owns just under 10% of iMDx.
As of the April 27, 2026 record date, iMDx had 32,288,039 common shares outstanding. The filing also details board independence, committee structures, a clawback policy, an insider trading policy that prohibits hedging, and 2024–2025 compensation and equity awards for directors and named executive officers.